/KLTO
KLTO Stock - Klotho Neurosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$0.39+7.00%
+$0.03 (+7.00%) • Dec 19
40
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.23
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.43
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KLTO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.38 – $0.39
TARGET (TP)$0.45
STOP LOSS$0.36
RISK/REWARD1:2.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.42
52W High$3.91
52W Low$0.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-5,540,236 | $-631,322 | $-574,374 | $-1,109,069 |
| Net Income | $-6,150,372 | $-707,458 | $-598,593 | $-1,109,025 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-0.32 | $-0.00 | $-0.00 | $-0.00 |
Company Overview
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
KLTOBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.05
Q4 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | — | $-0.05 | — | — |
Q3 2025 | Aug 18, 2025 | — | $-0.12 | — | — |
Q1 2025 | Mar 31, 2025 | — | $-0.07 | — | — |
Q1 2025 | Feb 25, 2025 | — | — | — | — |
Q4 2024 | Nov 19, 2024 | — | $-0.18 | — | — |
Q3 2024 | Aug 19, 2024 | — | $-0.03 | — | — |
Q2 2024 | Jun 30, 2024 | — | $-0.03 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.00 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.00 | — | — |
Latest News
Klotho Neurosciences Files Prospectus For Offer And Resale By Selling Stockholders Of Up To 34.9M Shares Of Common Stock
➖ NeutralBenzinga•Dec 5, 2025, 10:33 PM
Klotho Neurosciences Q3 EPS $(0.05) Up From $(0.18) YoY
📈 PositiveBenzinga•Nov 13, 2025, 10:42 PM
Reported Earlier, Klotho Neurosciences Ends Letter Of Intent With Turn Biotechnologies To Focus On Anti-Aging Protein Research And Longevity Therapies
➖ NeutralBenzinga•Oct 8, 2025, 07:08 AM
Klotho Neurosciences Signs Letter of Intent To Acquire Assets From Turn Biotechnologies, Including Turn's Epigenetic Reprogramming of Age Platform And eTurna RNA Delivery System As Well As Co-Development Partnership Worth Up To $300M
📈 PositiveBenzinga•Sep 30, 2025, 12:33 PM
Klotho Neurosciences Q2 EPS $(0.12) Down From $(0.03) YoY
📉 NegativeBenzinga•Aug 18, 2025, 01:50 PM
Klotho Neurosciences Highlights Pipeline Progress Toward $8B Neurodegenerative Market; Accelerates KLTO-202 Preclinical and IND-Enabling Studies
📈 PositiveBenzinga•Aug 18, 2025, 12:37 PM
Frequently Asked Questions about KLTO
What is KLTO's current stock price?
Klotho Neurosciences, Inc. (KLTO) is currently trading at $0.39 per share. The stock has moved +7.00% today.
What is the analyst price target for KLTO?
No analyst price targets are currently available for this stock.
What sector is Klotho Neurosciences, Inc. in?
Klotho Neurosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KLTO's market cap?
Klotho Neurosciences, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does KLTO pay dividends?
No, Klotho Neurosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCVKD
Cadrenal Therapeutics, Inc. Common Stock
$7.11
Mkt Cap: $0.0B
IBIO
iBio, Inc.
$1.98
Mkt Cap: $0.0B
MTVA
MetaVia Inc.
$8.62
Mkt Cap: $0.0B
NERV
Minerva Neurosciences, Inc.
$4.04
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
RLYB
Rallybio Corporation
$0.79
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to KLTO for comparison